Diamyd Medical AB (OSTO:DMYD B) Total Liabilities: kr147.23 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:DMYD B Diamyd Medical AB OSTO:DMYD B
41 GF Score
Price kr1.01
GF Value kr13.67
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB Total Liabilities?

Diamyd Medical AB OSTO:DMYD B -0.39% 41 Total Liabilities is kr147.23 Mil as of May. 2026. GuruFocus rates OSTO:DMYD B with a GF Score™ of 41/100 and a GF Value™ of kr13.67 (Possible Value Trap). The stock has 3 warning signs investors should review.

Diamyd Medical AB's Total Liabilities for the quarter that ended in May. 2026 was kr147.23 Mil.

Diamyd Medical AB's quarterly Total Liabilities increased from Nov. 2025 (kr70.83 Mil) to Feb. 2026 (kr83.84 Mil) and increased from Feb. 2026 (kr83.84 Mil) to May. 2026 (kr147.23 Mil).

Diamyd Medical AB's annual Total Liabilities increased from Aug. 2023 (kr36.41 Mil) to Aug. 2024 (kr71.12 Mil) and increased from Aug. 2024 (kr71.12 Mil) to Aug. 2025 (kr72.64 Mil).

Diamyd Medical AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Diamyd Medical AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB Total Liabilities Chart

Diamyd Medical AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.18 22.15 36.41 71.12 72.64

Diamyd Medical AB Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.40 72.64 70.83 83.84 147.23
OSTO:DMYD B
41GF Score
Diamyd Medical AB OSTO:DMYD B
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamyd Medical AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Diamyd Medical AB's Total Liabilities for the fiscal year that ended in Aug. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=27.483+(0+45.044
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.113+0)
=72.64

Total Liabilities=Total Assets (A: Aug. 2025 )-Total Equity (A: Aug. 2025 )
=352.638-279.998
=72.64

Diamyd Medical AB's Total Liabilities for the quarter that ended in May. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.719+(0+124.513
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=147.23

Total Liabilities=Total Assets (Q: May. 2026 )-Total Equity (Q: May. 2026 )
=406.626-259.394
=147.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr147.23 Mil mean?
Diamyd Medical AB (OSTO:DMYD B) has a Total Liabilities of kr147.23 Mil as of May. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Diamyd Medical AB and its competitors.
Is Diamyd Medical AB's Total Liabilities too high?
Diamyd Medical AB's current Total Liabilities is kr147.23 Mil. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Total Liabilities compare to VRTX and REGN?
Diamyd Medical AB's Total Liabilities of kr147.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Diamyd Medical AB and its competitors. Diamyd Medical AB's current Total Liabilities is kr147.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (OSTO:DMYD B) is currently considered Possible Value Trap. The stock's GF Value™ is kr13.67, compared to a current price of kr1.01 — trading 92.6% below its estimated fair value. The current Total Liabilities is kr147.23 Mil. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Diamyd Medical AB (OSTO:DMYD B), the current Total Liabilities is kr147.23 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamyd Medical AB (OSTO:DMYD B) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued. The current stock price of kr1.01 is trading 92.6% below its estimated GF Value™ of kr13.67. GuruFocus considers Diamyd Medical AB to be Possible Value Trap.

Key valuation signals for OSTO:DMYD B:

  • Total Liabilities: kr147.23 Mil
  • GF Value™: kr13.67 vs. price of kr1.01 (92.6% below fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the OSTO:DMYD B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diamyd Medical AB Business Description

Other Exchanges DMN:Germany
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score

Get the complete analysis for OSTO:DMYD B

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.01
Price
kr13.67
GF Value